SBC Occupiers Lunch / BioWednesday: How Ready Are We for Advanced Therapies?

  • Wednesday, 20 November 2019, 11:30 AM to 2:00 PM

Wednesday 20th November 2019, 11:30 – 14:00

Advanced therapeutics refer to medicines based on genes, tissues and cells. They offer new opportunities for treatments in areas of high un-met needs.

In order to adopt these medicines into standard healthcare, there needs to be consideration of the differences to pharmaceuticals and biologics and the significantly more complicated supply chain that they require. This includes challenges around shelf-life of therapies, manufacturing close to treatment, feasibility of large batches and reducing costs, to name but a few.

Our BioWednesday will look at the manufacturing challenges that we need to tackle in order to deliver advanced therapies to patients. It will feature examples of excellence that are helping to scale-up manufacturing  and ultimately help to implement these therapies in the long term for greater numbers of patients.


11.30 Registration and networking over tea and coffee

12.00 Intro to SBC 

12.10 Presentations from Manufacturers and Therapeutics Organisations on how they’re accelerating cell and gene therapies, particularly focusing on the manufacturing challenges they feel they are addressing, lessons learnt and things to consider when scaling from pre-clinical to clinical.  

Speakers include:

     • Matthew Miell, Viral Vector Group Leader, GE Healthcare

     • Sharon Brownlow, Head of Collaborations - Manufacturing Centre, Cell & Gene Therapy Catapult

     • Joanna Vlahopoulou, Founder, Procellia

     • Dara Henry, VP Operations and Business Development, Achilles Therapeutics Ltd

13.15 Lunch / Round table discussions with presenting organisations

14.15 End


One Nucleus Members: Free

Non-Members: £50 +VAT

Academics: please contact

Click here for more info


Stevenage Bioscience Catalyst is the UK's leading open innovation campus with a focus on therapeutics.

Learn more

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.